Investment
Features
FeesSafety
Academy
More
Pluang+

Dutch court orders halt to unapproved semaglutide nasal spray infringing Novo Nordisk's patent rights

Market News
05 Aug 2026
Na
View Source
Bullish
Dutch court orders halt to unapproved semaglutide nasal spray infringing Novo Nordisk's patent rights

The District Court of The Hague granted Novo Nordisk a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., stopping the sale of an unapproved compounded semaglutide nasal spray that infringes Novo Nordisk's patent. The court ruling protects patients by enforcing regulatory standards for medicine safety and efficacy, requiring Ceban to remove product listings and reimburse legal costs. Novo Nordisk emphasizes that no nasal spray form of semaglutide is approved and continues to defend its intellectual property to ensure patient safety and support medical innovation.

More News (NVO)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App